首页> 外文会议>Recent advances in clinical medicine >Research on the proliferation and drug-resistance of human BTSCs
【24h】

Research on the proliferation and drug-resistance of human BTSCs

机译:人类BTSCs的增殖和耐药性研究

获取原文
获取原文并翻译 | 示例

摘要

Brain tumor stem cells (BTSC_s) have been implied to play an important role in genesis and development of glioma. However, their characteristics on proliferation and drug-resistance are uncertain thoroughly. In this experiment, some of the biological characteristics about BTSC_s were explored. Twenty cases of different grades of human glioma tissues were obtained from clinic. After tumors were dissociated, the sample was triturated into the single cells and then filtered. The primary glioma cells were collected and cultured in the DMEM/F12 medium containing 20ng/μm of EGF, LIF and bFGF respectively. At the 5~(th) day after culture, the suspensioned cellular spheres were harvested and then both the CD133~+and CD 133~- cells were purified by immunomagnetic beads. The BTSCs were identified by testing the expression of CD133, NSE and GFAP, along with the culture process. CCK.8 was used to assay the proliferating situation of CD133~+ cells in the different grade gliomas, and to compare the drug-resistance between the CD133~+ and CD 133~ - cells in the medium containing differentrnconcentrations (including 1 Oμg/ml、20μg/ml、 40μg/ml , and 80μg/ml) of teniposide (VM-26), arnkind of drug against gliomas. The results showed that the CD133~+ cells could regenerate by self-renewal, then generate and different into NSE~+cells and GFAP~+ ones respectively. CD133~+ cells in the high grade of gliomas showed the faster generation than the ones in the low grade. The number of survived CD133~+ cells in the medium containing VM-26 (no matter any conentration) was much more than the CD133~ -.ones in it. Therefore, it was implied that the CD133~+ BTSC_s existed in the glioma tissues possessed the more tolerant ability to the VM-26, and could proliferate much more easily in the high grade glioma..
机译:已经暗示脑肿瘤干细胞(BTSC_s)在神经胶质瘤的发生和发展中起重要作用。但是,它们在增殖和抗药性方面的特征尚不确定。在该实验中,探索了关于BTSC_s的一些生物学特性。从诊所获得了20例不同等级的人类神经胶质瘤组织。解离肿瘤后,将样品研磨成单细胞,然后过滤。收集原代神经胶质瘤细胞,并在分别含20ng /μmEGF,LIF和bFGF的DMEM / F12培养基中培养。培养后第5天,收集悬浮的细胞球,然后用免疫磁珠纯化CD133 +和CD 133-细胞。通过测试CD133,NSE和GFAP的表达以及培养过程来鉴定BTSC。 CCK.8用于检测不同级别胶质瘤中CD133〜+细胞的增殖情况,比较CD133〜+和CD 133〜-细胞在不同浓度(含10μg/ ml)培养基中的耐药性。 ,20μg/ ml,40μg/ ml和80μg/ ml的替尼泊苷(VM-26),是一种抗神经胶质瘤的药物。结果表明,CD133〜+细胞可以通过自我更新而再生,然后分别分化为NSE〜+细胞和GFAP〜+细胞。高等级神经胶质瘤中的CD133〜+细胞比低等级神经胶质瘤中的CD133〜+细胞产生更快。含有VM-26的培养基(无论浓度如何)中存活的CD133〜+细胞的数量远远大于其中的CD133〜.。因此,这提示存在于神经胶质瘤组织中的CD133〜+ BTSC_s对VM-26具有更强的耐受能力,在高级别神经胶质瘤中更容易增殖。

著录项

  • 来源
  • 会议地点 Cambridge(GB);Cambridge(GB);Cambridge(GB);Cambridge(GB);Cambridge(GB);Cambridge(GB);Cambridge(GB);Cambridge(GB)
  • 作者单位

    Neurosurgery Institute of Guangdong, Southern Medical University 258# Gongye Road, Guangzhou510282, Guangdong Province P. R. of China;

    Neurosurgery Institute of Guangdong, Southern Medical University 258# Gongye Road, Guangzhou510282, Guangdong Province P. R. of China;

    Neurosurgery Institute of Guangdong, Southern Medical University 258# Gongye Road, Guangzhou510282, Guangdong Province P. R. of China;

    Neurosurgery Institute of Guangdong, Southern Medical University 258# Gongye Road, Guangzhou510282, Guangdong Province P. R. of China;

    Neurosurgery Institute of Guangdong, Southern Medical University 258# Gongye Road, Guangzhou510282, Guangdong Province P. R. of China;

  • 会议组织
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 临床医学;
  • 关键词

    glioma; brain tumor stem cells (BTSC_s); CD133; teniposide (VM-26);

    机译:胶质瘤脑肿瘤干细胞(BTSC_s); CD133;替尼泊苷(VM-26);

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号